glp 1 drugs contraindications Diabetes mellitus: GLP-1 A number of drugs to treat diabetes mellitus have become available in recent years. Much research has focused around the role of glucagon-like peptide-1 (GLP-1), a hormone The GLP-1 Agonists and Obesity:

A separate body of meta-analytic work examining blood glucose outcomes has reported reductions in fasting plasma glucose, HbA1c, and postprandial glucose across multiple trials

Semaglutide reduces A1c by 1.0 to 1.5 percentage points on average

Their clinical utility, however, differs by formulation and pharmacokinetic profile

Sajana Maharjan also states in the press release that while many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings in our study reinforce that exercise cannot be optional for people taking these medications

The Danish guidelines suggest a dosage of 1.8 mg daily in women with diabetes or 3.0 mg daily in women with obesity for liraglutide, and 1.0 mg once weekly for semaglutide for treatment of patients with type 2 diabetes or 2.4 mg once weekly for patients with obesity (Dansk Endokrinologisk Selskab, 2023)

In the vascular system, oxidative stress in diabetes activates ROS-mediated Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascades, promoting autophagy in endothelial cells while downregulating HDAC6 expression, which impairs cell migration and adhesion